Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arsenic Trioxide and Ascorbic Acid in Myelodysplastic Syndromes
NCT00803530Phase 2Terminated
- Sponsor
- Fondazione Italiana Sindromi Mielodisplastiche
- Start
- Sep 2005
- Primary completion
- Jan 2007
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of arsenic trioxide in myelodysplastic syndrome (MDS), sponsored by Fondazione Italiana Sindromi Mielodisplastiche. Started Sep 2005; status: terminated.
02
Drugs
arsenic trioxide
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00803530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00803530.